Antares Pharma, Inc. (NASDAQ:ATRS)

CAPS Rating: 3 out of 5

The Company develops, produces and markets pharmaceutical delivery products, including transdermal gels, oral fast melting tablets and reusable needle-free and disposable mini-needle injector systems.

Results 1 - 20 of 38 : 1 2 Next »

Recs

0
Member Avatar DonaldSS (< 20) Submitted: 7/7/2014 1:03:04 PM : Outperform Start Price: $2.66 ATRS Score: -5.63

after CEO quick leave to smaller co. sales and announced uncoming events don't change.

Recs

0
Member Avatar naughtyguy (33.00) Submitted: 4/16/2014 2:48:59 PM : Outperform Start Price: $3.01 ATRS Score: -23.92

If ita gets much lower in price I'm buying some!

Recs

0
Member Avatar Rilac (98.63) Submitted: 10/14/2013 2:54:24 PM : Outperform Start Price: $4.73 ATRS Score: -65.58

as of october 14th, Antares's product otrexup has been approved. following the news, Antares popped 5%. Otrexup's approval was an expected occurence hence the meager movement upward. Im expecting another runup in the short term. However im skeptic of Oxtrexup's long term sales, so i wouldn't trade this for the long term.

Recs

0
Member Avatar louchios50 (< 20) Submitted: 10/2/2013 7:34:56 PM : Outperform Start Price: $4.32 ATRS Score: -61.75

Research development m&a

Recs

0
Member Avatar Shadowplay1 (< 20) Submitted: 12/6/2012 3:24:14 PM : Outperform Start Price: $3.83 ATRS Score: -77.47

Antares is gearing up for what I think will be a block bluster of a drug and that is Vibex MTX. Management has already said they plan to file an NDA with the FDA in Q1 of 2013 and when they do the stock should take off in anticipation of an early release from the FDA. Management has already done their own private studies with MTX and had an astonishing 96% approval rating. At a little under $4 a share, I think this could really benefit someones portfolio for the next two to three years.

Recs

0
Member Avatar FoolyOut (39.73) Submitted: 7/19/2012 7:28:48 PM : Outperform Start Price: $3.81 ATRS Score: -77.64

Along with gel transdermal delivery systems for drugs, they have pioneered and exploited the use of disposable pens which deliver Epinephrine for allegic reactions as well as adjustable dosage pens for insulin delivery and methotrexate for arthritis pain. Recently approved by FDA for Metho-pens. Owned since it was .89 per share.

Recs

0
Member Avatar stainsolution (27.31) Submitted: 7/17/2012 6:01:49 AM : Outperform Start Price: $2.99 ATRS Score: -62.71

ATRS---in at $2.99. Stock is over $5/sh now. My CAPS page doesn't reflect.

Recs

0
Member Avatar dmsrz8 (52.88) Submitted: 7/12/2012 7:42:36 PM : Outperform Start Price: $3.81 ATRS Score: -77.64

I really feel like this is a company worth while to everyone in times of uncertainty. Though there is some volatility associated with the company related to the overall health of the market, with a balance sheet that has NO debt, and several items in development and out already, not to mention a recent partnership with Pfiser, this company really seems like it is an absolute STEAL right now below $5 a share. Will only go up.

Recs

0
Member Avatar dataguru61 (55.96) Submitted: 6/20/2012 7:32:12 AM : Outperform Start Price: $3.81 ATRS Score: -77.64

Outstanding Product Line

Recs

0
Member Avatar RXDOC73 (99.37) Submitted: 6/4/2012 10:09:37 AM : Outperform Start Price: $2.83 ATRS Score: -67.93

Buy out target

Recs

0
Member Avatar Bsav88atty (< 20) Submitted: 4/17/2012 11:48:21 PM : Outperform Start Price: $2.94 ATRS Score: -59.92

Great low risk/ high reward investment that will finally turn a profit this year. In addition to the company's growing list of partners and deep pipeline, most exciting is the revenue potential of its proprietary drug-device combo products, including Vibex MTX and three undisclosed products. With an MTX commercial launch in 2014 followed by a likely launch of QS1 in 2015 or 2016, the royalty and margin deals the company has now will be just window dressing.

Recs

0
Member Avatar Joshdwashere (< 20) Submitted: 4/3/2012 9:52:07 PM : Underperform Start Price: $3.24 ATRS Score: +66.38

Long term I feel this will be worthwhile

Recs

0
Member Avatar RBuskey106 (42.76) Submitted: 3/24/2012 7:22:39 PM : Outperform Start Price: $2.96 ATRS Score: -58.83

Love the chart.

Recs

0
Member Avatar gWinkel33 (< 20) Submitted: 3/23/2012 11:40:30 PM : Outperform Start Price: $3.40 ATRS Score: -69.78

Will have good growth and has a good product line.

Recs

0
Member Avatar TallCountry (26.15) Submitted: 3/8/2012 6:16:04 PM : Outperform Start Price: $3.00 ATRS Score: -62.99

just sign licensing agreement with pfizer.

Recs

0
Member Avatar micro1943 (< 20) Submitted: 1/14/2012 2:14:16 PM : Outperform Start Price: $2.29 ATRS Score: -44.00

Excellent management, solid stable of products and positive earnings which will be coming within a few months. PS yes I have placed plenty of money behind these comments.

Recs

0
Member Avatar dheatguy (< 20) Submitted: 1/4/2012 1:55:01 PM : Outperform Start Price: $2.08 ATRS Score: -35.35

Major picks by TEVA and PFE and 7 drug pipeline -- not a one trick pony.

Recs

0
Member Avatar gnikflog (< 20) Submitted: 1/1/2012 2:00:54 PM : Outperform Start Price: $2.18 ATRS Score: -43.31

Too many Positives

Recs

0
Member Avatar oldman144 (< 20) Submitted: 12/31/2011 9:50:23 AM : Outperform Start Price: $2.18 ATRS Score: -43.31

Actual monetary cost to Antares(AIS) for the failure of Biosante failed test was zero. AIS is not a one trick pony and their delivery systems can be used for applications of many drugs now and in the future.

Recs

0
Member Avatar AverageRob (< 20) Submitted: 8/26/2011 12:18:08 PM : Outperform Start Price: $2.24 ATRS Score: -62.30

Antares has enough capital on hand to cover current costs for the next 2 years. With new drugs like the OAB topical gels now in phase III trials we could see a large share price jump if the FDA approves the drugs and can then be exposed to the market of around 2.1B market cap for the specific OAB drug. [Other new gel products include birth-control, Menonpasal, and a very new themed "womens viagra"] Hopefully we could see 100% gains in this pharma company or maybe even a possible buyout at one point.

Results 1 - 20 of 38 : 1 2 Next »

Featured Broker Partners


Advertisement